Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
about
Cost-Effectiveness of Disease-Modifying Therapies in Multiple SclerosisMultiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparatorCost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the futureBayesian variable selection in cost-effectiveness analysis.Modulation of autoimmunity with artificial peptidesCost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.Assessing cost-effectiveness in the management of multiple sclerosis.Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.Costs and quality of life of patients with multiple sclerosis in EuropeCost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS.Interferon-beta treatment for multiple sclerosis.Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.Quantitative risk-benefit analysis of natalizumab.UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.Multiple sclerosis: relapses, resource use, and costs.Let cost effectiveness models be open to scrutinyCost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran.Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy.Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.Replicating Health Economic Models: Firm Foundations or a House of Cards?The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.Cost-effectiveness of natalizumab in multiple sclerosis.The payer's perspective: What is the burden of MS and how should the patient's perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.Assessing the economic challenges posed by orphan drugs: A comment on Drummond et alPharmacoeconomics and clinical trials in multiple sclerosis: baseline data from the European UnionRationing and deprivation: disease-modifying therapies for multiple sclerosis in the United KingdomPharmacoeconomics
P2860
Q22252598-D20F32D4-AC4E-4914-B0FA-7116E27CA8B2Q28749656-95F80AA8-C0A1-4004-A800-6EFF99BFEC71Q30651607-36C7F8BD-C5EA-43DE-B33D-ECB23270AA92Q31037061-60A409ED-9394-43FB-A5BA-BFA9D233496EQ33397837-4881AC44-8149-4128-8949-DFB5AF9BB1C8Q33859002-2F5F7DA1-5269-4836-BEFD-B020D12836A4Q34288089-4C09C7D5-724A-4B52-872B-9DCEF8E4E0F6Q35119597-0FB83954-2FBA-4F72-8C58-F8514B5C27D0Q35205463-75BBADEF-8642-4AA6-9F29-CE54FB6260A7Q35906921-48C7811B-9C25-4407-B8B9-97FB24DC3193Q36142777-A2507A2C-E42A-4BF1-898D-3A4C3C73E970Q36469022-A688F39F-45EB-4367-8DC2-CA46ACA6F71AQ36699401-D5A3F75F-34FC-474F-A96A-A51337CCAD29Q36963178-059B844B-E433-4F89-83E7-07F1BF1EE285Q36968664-0C098E2B-E228-4DCA-A9E7-16F1102362B5Q37150465-B436C990-5390-429F-B7A5-55D2D5C72315Q37178959-305D3008-B7D8-4558-9B52-FC7AC9FA1F59Q37517082-C58E016E-09B8-4DAB-A732-A0045DE7F9B8Q37519608-33317FE2-A0A8-4138-A48C-F0CDBEB8EEA3Q38097527-520AB200-97A9-4450-9923-2C7D971627CCQ38103515-5DE99B45-3F37-4824-94E7-208AD2C85110Q38197076-BA2B95E1-8273-4D3A-8497-F7ED3F1F6548Q39300217-9606E1B9-1C46-4986-A751-B1530513AC1DQ40226939-7E031BCA-4F33-403A-8970-BA330DECA346Q40464842-55A2DA29-A8B0-4CA0-89BC-09CC5957D461Q42566217-29DD7357-22A5-4D17-AB51-823AF59F3A64Q42905696-51AB5B5D-9D92-4EBC-AB76-F54154662F49Q43255273-8A737A83-30D6-44FA-A604-1C0936755A03Q43280735-550CBE25-45BA-4822-9BDD-D86462B19899Q44670941-CEA4675A-ABB6-412E-9948-639B735D6725Q46485291-3392AEFC-D4FA-44B0-9E3D-84464A7A93F5Q47329445-52122A1E-BC23-4A65-9CD4-42E9961CC060Q51073340-CCFB08EC-7E7F-4B13-9125-4AB5AE7EA288Q51146514-D5ED0E2D-AEC9-435C-B825-5DADBDB353A5Q52985191-367E3DA0-1C4D-47C5-9042-AE3D79A99C14Q53832244-8C193FA4-AB65-4A81-93BC-6FFCCCC938BEQ56018117-E6BE2595-5BE6-44BE-8820-917725270FC8Q56698309-D4576F01-4115-4BF4-BF91-FE46187EEB8BQ57573402-07563605-431D-4389-9068-61CA901C2BF1Q57774074-6B455A88-F6AA-4C11-9BD8-93B28180B792
P2860
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Modelling the cost effectivene ...... atments in multiple sclerosis.
@ast
Modelling the cost effectivene ...... atments in multiple sclerosis.
@en
Modelling the cost effectivene ...... atments in multiple sclerosis.
@nl
type
label
Modelling the cost effectivene ...... atments in multiple sclerosis.
@ast
Modelling the cost effectivene ...... atments in multiple sclerosis.
@en
Modelling the cost effectivene ...... atments in multiple sclerosis.
@nl
prefLabel
Modelling the cost effectivene ...... atments in multiple sclerosis.
@ast
Modelling the cost effectivene ...... atments in multiple sclerosis.
@en
Modelling the cost effectivene ...... atments in multiple sclerosis.
@nl
P2093
P2860
P356
P1433
P1476
Modelling the cost effectivene ...... eatments in multiple sclerosis
@en
P2093
Chris McCabe
Cost Effectiveness of Multiple Sclerosis Therapies Study Group
David H Miller
Jim Chilcott
Karl Claxton
Keith Abrams
Nicola J Cooper
Paul Tappenden
P2860
P304
522; discussion 522
P356
10.1136/BMJ.326.7388.522
P407
P577
2003-03-01T00:00:00Z